Georg Nebgen

Dr. Nebgen is a of NGN Capital.
He joined from MPM Capital where he had previously been Principal at MPM Capital in Boston and Managing Director of MPM Capital GmbH.
Prior to this, Dr. Nebgen was with Schering-Plough Corporation, as Managed Care Area Manager for New England.
His responsibilities included contracting the reimbursement of Schering-Plough’s ethical pharmaceutical products and services with managed care organizations as well as leading sales pull-through activities of the field forces.
Prior to this, Dr. Nebgen had served in Schering-Plough's subsidiary in Switzerland as Business Unit Head, Oncology & Biotech and Business Unit Head, Cardiovascular & CNS.
Dr. Nebgen joined Schering-Plough from F.
Hoffmann-La Roche, where he led as Technical Project Leader the global research & development team for Invirase/Fortovase its NDA filing, FDA approval, and subsequent product launch in the United States.
Dr. Nebgen obtained his doctorate in Pharmaceutical Technology Sciences from the University of Bonn, Germany and his executive MBA from the University of St. Gallen, Switzerland.